Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Jul 18, 2017; 8(7): 531-535
Published online Jul 18, 2017. doi: 10.5312/wjo.v8.i7.531
Published online Jul 18, 2017. doi: 10.5312/wjo.v8.i7.531
Use of recombinant human bone morphogenetic protein-2 in spine surgery
Marios Lykissas, Department of Spine Surgery, Metropolitan Hospital, 18547 Athens, Greece
Ioannis Gkiatas, Orthopaedic Department, University Hospital of Ioannina, 45500 Ioannina, Greece
Author contributions: Lykissas M performed the majority of the writing, collecting all the bibliography that was used; Gkiatas I performed writing as well as input in writing the paper and designed the outline.
Conflict-of-interest statement: There is no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Marios Lykissas, MD, Department of Spine Surgery, Metropolitan Hospital, Ethnarxou Makariou 9 & El. Venizelou 1, 18547 Athens, Greece. mariolyk@yahoo.com
Telephone: +30-694-4591915 Fax: +30-210-4814887
Received: December 18, 2016
Peer-review started: December 20, 2016
First decision: January 28, 2017
Revised: February 5, 2017
Accepted: April 18, 2017
Article in press: April 20, 2017
Published online: July 18, 2017
Peer-review started: December 20, 2016
First decision: January 28, 2017
Revised: February 5, 2017
Accepted: April 18, 2017
Article in press: April 20, 2017
Published online: July 18, 2017
Core Tip
Core tip: The use of recombinant human bone morphogenetic protein-2 is widely used in spine surgery not only in approved indications but also in off-label indications. Despite its ability to promote fusion there are many reported disadvantages. That’s why the Yale University Open Data project aims to serve both the patients but also the companies which fund the vast majority of research in medical products.